
Does Lemon Candy Decrease Salivary Gland Damage After Radioiodine Therapy for Thyroid Cancer?

Kunihiro Nakada, MD, PhD¹; Tetsuya Ishibashi, MD¹; Toshiki Takei, MD¹; Kenji Hirata, MD¹; Katsura Shinohara, MD¹; Seiichi Katoh, MD¹; Sonji Zhao, MD, PhD¹; Nagara Tamaki, MD, PhD¹; Yasushi Noguchi, MD²; and Shiro Noguchi, MD, PhD²

¹Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan; and ²Noguchi Thyroid Clinic and Hospital Foundation, Beppu, Japan

Salivary gland dysfunction is one of the common side effects of high-dose radioiodine therapy for thyroid cancer. The purpose of this study was to determine whether an early start of sucking lemon candy decreases salivary gland injury after radioiodine therapy. **Methods:** The incidence of the side effects of radioiodine therapy on the salivary glands was prospectively and longitudinally investigated in 2 groups of patients with postsurgical differentiated thyroid cancer with varying regimens for sucking lemon candy. From August 1999 to October 2000, 116 consecutive patients were asked to suck 1 or 2 lemon candies every 2–3 h in the daytime of the first 5 d after radioiodine therapy (group A). Lemon candy sucking was started within 1 h after radioiodine ingestion. From November 2000 to June 2002, 139 consecutive patients (group B) were asked to suck lemon candies in a manner similar to that of group A. In the group B, lemon candies were withheld until 24 h after the ingestion of radioiodine. Patients with salivary gland disorders, diabetes, collagen tissue diseases, or a previous history of radioiodine therapy or external irradiation to the neck were excluded. Thus, 105 patients in group A and 125 patients in group B were available for analysis. There were no statistical differences in the mean age (55.2 y vs. 58.5 y), average levels of serum free thyroxine (L-3,5,3',5'-tetraiodothyronine) (0.40 ng/dL vs. 0.47 ng/dL), and the mean dose of ¹³¹I administered (3.96 GBq vs. 3.87 GBq) between the 2 groups. The onset of salivary side effects was monitored during hospital admission and regular follow-up on the basis of interviews with patients, a visual analog scale, and salivary gland scintigraphy using ^{99m}Tc-pertechnetate. When a patient showed a persistent (>4 mo) dry mouth associated with a nonfunctioning pattern on salivary gland scintigraphy, a diagnosis of xerostomia was established. **Results:** The incidences of sialoadenitis, hypogeusia or taste loss, and dry mouth with or without repeated sialadenitis in group A versus group B were 63.8% versus 36.8% ($P < 0.001$), 39.0% versus 25.6% ($P < 0.01$), and 23.8% versus 11.2% ($P < 0.005$), respectively. Permanent xerostomia occurred in 15 patients in group A (14.3%) and 7 patients in group B (5.6%) ($P < 0.05$). In both groups, bilateral involvement of the parotid gland was the most fre-

quently seen and was followed by bilateral involvement of the submandibular gland. **Conclusion:** An early start of sucking lemon candy may induce a significant increase in salivary gland damage. Lemon candy should not be given until 24 h after radioiodine therapy.

Key Words: salivary gland; radioiodine therapy; thyroid cancer; amifostine

J Nucl Med 2005; 46:261–266

Salivary glands have the sodium iodine symporter (1–3). Therefore, radioiodine ¹³¹I to treat patients with postsurgical thyroid cancer is taken up in the salivary glands. The concentration of ¹³¹I in the salivary gland, which is about 30–40 times of that in the plasma (1), is sufficient to cause salivary gland injury. Salivary dysfunction is the most common side effect associated with high-dose radioiodine ¹³¹I therapy for differentiated thyroid cancer (1–10). Additionally, salivary gland dysfunction can be observed even when the dose of ¹³¹I administered is relatively low (10). Because xerostomia impairs the quality of life of a patient for the life-long period, prevention of salivary damage is an important issue. So far, the only successful strategy to prevent salivary damage after ¹³¹I therapy is the prophylactic use of 2-(S)-(3-aminopropylamino)ethylphosphorothioic acid (amifostine) (11–14). Unfortunately, availability of this drug is currently limited. Salivation-inducing snacks, such as lemon candy, have been also presumed to be helpful in prevention of salivary side effects of ¹³¹I therapy (15,16). However, there has been no established evidence that lemon candy actually decreases injury of the salivary gland after ¹³¹I therapy. Despite its frequent use, the optimal regimen of lemon candy in ¹³¹I therapy remains unestablished. The purpose of this study was to determine whether an early start of sucking lemon candy decreases the side effects of radioiodine therapy on the salivary glands.

Received Jul. 16, 2004; revision accepted Sep. 27, 2004.
For correspondence or reprints contact: Kunihiro Nakada, MD, PhD, Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Niushi-7, Kita-ku, Sapporo, 060-8638, Japan.
E-mail: metnakada@yahoo.co.jp

MATERIALS AND METHODS

Patient Groups

Two groups of postsurgical differentiated thyroid cancer patients, who were referred to our institute for ^{131}I therapy to ablate the remnant thyroid tissue or to treat metastatic tumor, were prospectively studied under varying regimens of lemon candy sucking. The ingredients of the candy consist of sugar, glucose syrup, cornstarch, vegetable oil, ascorbic acid, condensed lemon juice, sorbitol, and natural flavorings. A container of lemon candy (110 g per container; 429 calories) contains 0.1 g of protein, 5.3 g of fat, 97.6 g of carbonate, 370 mg of sodium, and 3,000 mg of vitamin C. From August 1999 to October 2001, 116 consecutive patients were instructed to suck 1 or 2 lemon candies every 2–3 h in the daytime of the first 5 d after ^{131}I therapy (group A). Sucking of lemon candy was started within an hour after ingestion of ^{131}I . From November 2000 to June 2002, 139 consecutive patients (group B) were instructed to suck lemon candy in a manner similar to that of group A. However, lemon candies were not administered until 24 h after the ingestion of ^{131}I . In both groups, thyroid hormone replacement was withdrawn 3 wk before ^{131}I therapy. A low-iodine diet was started 7 d before ^{131}I therapy. The dose of ^{131}I administered ranged from 2.66 to 5.55 GBq. All patients were instructed to drink as much water or iodine-free beverages as possible throughout the first 4 d after the ingestion of ^{131}I . In patients who had developed nausea due to hypothyroidism or had difficulty in drinking a large amount of water, dripped infusion of saline (500–1,000 mL/d) was performed. Patients with a previous history of salivary gland disorders, diabetes, collagen tissue disease, or previous ^{131}I therapy or external irradiation to the neck were excluded from the study. Thus, 105 patients in the group A and 125 patients in the group B were available for analysis. There were no significant differences in the mean age, sex, and mean levels of free thyroxine (L-3,5,3',5'-tetraiodothyronine) (FT_4) (ng/dL) at radioiodine therapy and the average dose of ^{131}I administered between the 2 groups (Table 1). The incidence of side effects on the salivary glands after ^{131}I therapy was prospectively determined. The onset of sialadenitis, taste dysfunction (hypogeusia or taste loss), dry mouth, and xerostomia after ^{131}I therapy was monitored during the period of hospitalization and in the regular follow-up (1- to 6-mo interval) for >24 mo on the basis of interviewing patients, including a questionnaire, a 10-cm visual analog scale (VAS), and salivary gland scintigraphy using $^{99\text{m}}\text{TcO}_4^-$. Patients fasted for 2 h before salivary gland scintigra-

phy and were placed spine in the Water's position. After an intravenous injection of 147 MBq of $^{99\text{m}}\text{TcO}_4^-$, dynamic anterior images were acquired in a 256×256 matrix every 30 s for 30 min using a GCA-9300DI digital γ -camera system (Toshiba) equipped with a low-energy, high-resolution collimator. Lemon juice was administered using a straw at 20 min after injection as a stimulant of salivary discharge. Regions of interest were symmetrically drawn on the combined dynamic images in the bilateral parotid glands, submandibular glands, and backgrounds in the neck to determine time–activity curves for the 4 major salivary glands. Scan images and time–activity curves were interpreted by 2 independent nuclear medicine physicians with classification into 5 patterns: normal, mildly to moderately hypofunctioning, obstructive, severely hypofunctioning, and nonfunctioning (Fig. 1). When a patient complained of persistent dry mouth (>4 mo) associated with a nonfunctioning pattern on salivary gland scintigraphy, xerostomia was diagnosed. In patients with xerostomia, VAS and salivary gland scintigraphy were reexamined 4–6 mo later to determine whether the salivary gland dysfunction was reversible.

Statistical Analysis

Data are expressed as mean \pm SD. A nonpaired *t* test and χ^2 test were used for group comparisons. *P* values < 0.05 were considered significant.

RESULTS

Sialoadenitis and taste dysfunction were observed in 43 and 17 patients in group A and in 34 and 20 patients in group B, respectively. Sialadenitis occurred between 1 to 4 d after ^{131}I therapy. Taste dysfunction developed 4–60 d after ^{131}I therapy. Additionally, 24 patients in group A and 12 patients in group B experienced both sialoadenitis and taste dysfunction. A subjective dry mouth associated with or without repeated sialoadenitis became apparent 4–13 mo after ^{131}I therapy in 25 patients in group A and in 14 patients in group B, respectively. Of 25 patients in group A, 10 had a previous episode of sialadenitis, 3 had taste dysfunction, and 12 had both. Of 14 patients in group B, 6 had a previous episode of sialadenitis, 3 had taste dysfunction, and 5 had both. Subsequently, xerostomia was confirmed in 15 patients in group A and 7 patients in group B (Figs. 2 and 3) 7–17 mo after ^{131}I therapy. Eleven patients in group A and 5 patients of group B had either of the acute side effects of ^{131}I therapy on the salivary glands before development of xerostomia. However, 4 patients in group A and 2 patients in group B had xerostomia without preceding sialoadenitis or taste dysfunction. The incidences of sialoadenitis, taste dysfunction, and dry mouth in group A versus group B were 63.8% versus 36.8% (*P* < 0.001), 39.0% versus 25.6% (*P* < 0.01), and 23.8% versus 11.2% (*P* < 0.005), respectively (Table 2). Xerostomia occurred in 14.3% of patients in group A and 5.6% in group B (*P* < 0.05). Once developed, xerostomia was not improved in any of the patients during the follow-up period. The incidences of sialoadenitis, taste dysfunction, dry mouth, and xerostomia were significantly higher in group A than in group B. Bilateral involvement of the parotid glands was the most frequently noted, which was followed by bilateral involvement of the sub-

TABLE 1
Patient Characteristics

Characteristic	Group A	Group B
Start of sucking lemon candy	<1 h*	>24 h*
Patients available (<i>n</i>)	105	125
Age (y)	55.2 \pm 11.6	58.5 \pm 12.9
Sex (M/F)	15/90	14/111
Papillary/follicular	100/5	118/7
Ablation/metastatic disease	77/28	89/36
FT_4^\dagger (ng/dL)	0.39 \pm 0.29	0.44 \pm 0.20
Dose of ^{131}I (GBq)	3.96 \pm 0.41	3.87 \pm 0.65

*After ^{131}I ingestion.
†Normal range = 0.70–2.10 ng/dL.




FIGURE 1. Typical time-activity curves of $^{99m}\text{TcO}_4^-$ for bilateral parotid glands in patients with postsurgical thyroid cancer after high-dose radiodine therapy. Solid line is curve for right parotid gland; dashed line is curve for left parotid gland. (A) Normal: Lemon juice was administered at 20 min after injection of $^{99m}\text{TcO}_4^-$ (\downarrow). (B) Mild to moderately hypofunctioning (lower curve) and obstructive (upper curve). (C) Severely hypofunctioning. (D) Nonfunctioning.

mandibular glands and unilateral involvement of either parotid gland or parotid gland (Table 3). Five patients in group A and 2 patients in group B showed involvement of all 4 major glands.

DISCUSSION

To our knowledge, this is the first study to pose a question with regard to the use of a sialagogue immediately after ^{131}I

therapy for preventing radiation injury in the salivary glands. The incidence of sialadenitis, taste dysfunction, dry mouth, and permanent xerostomia was significantly higher in group A than in group B. Moreover, the incidences of dry mouth and xerostomia in group A were increased up to >2-fold of those in group B. An early start of sucking lemon candy did not contribute to reducing radiation injury from ^{131}I to the salivary glands.




FIGURE 2. Early and late side effects of high-dose radioiodine therapy on salivary glands in group A patients (pts).




FIGURE 3. Early and late side effects of high-dose radioiodine therapy on salivary glands in group B patients (pts).

The reported frequencies of salivary gland damage caused by ^{131}I therapy for thyroid cancer vary depending on the diagnostic strategy. Studies that investigated the incidence of salivary side effects of ^{131}I therapy by means of questionnaire showed a relatively low frequency of sialoadenitis or xerostomia (8,10). Studies including salivary gland scintigraphy in assessment of salivary function were associated with a higher incidence of side effects. An abnormal uptake or excretion of $^{99\text{m}}\text{TcO}_4^-$ on salivary scintigraphy was observed in about 73% of 33 patients treated with 3.69–38.7 GBq of ^{131}I (9). In 39 patients with subjective salivary symptoms after >37 GBq of ^{131}I , subsequent xerostomia was seen in 44%, whereas salivary gland dysfunction on salivary gland scintigraphy was observed in 65% of the patients (17). The status of lemon candy sucking was not described in these reports. Bohuslavizki et al. concluded that, despite the standard protection regimen using ascorbic acid as a sialogogue, radioiodine induced the loss of salivary gland parenchymal function (18). However, 83 of 106 patients in their study had benign thyroid diseases and the thyroid function at the time of ^{131}I therapy was not de-

scribed. Compared with those reports, the patients treated with amifostine had apparently fewer incidences of salivary dysfunction (11,12). We longitudinally investigated the incidences of side effects on the salivary glands after the initial ^{131}I therapy for postsurgical thyroid cancer. The acute side effects were diagnosed on the basis of subjective symptoms, while xerostomia was diagnosed by combination of VAS and salivary gland scintigraphy. Although the precise reason for our finding remains unknown, it is likely that there were certain relationships between the salivary side effects observed and the timing of starting to suck lemon candy since there was no significant difference in patient characteristics, preparations for the ^{131}I administered, and the dose of ^{131}I administered between the 2 groups.

There are possible explanations for the higher incidence of salivary side effects in group A than in group B. Sucking lemon candy has been recommended on the basis of assumptions that lemon candy accelerates clearance of radioiodine from the salivary glands and that the salivary gland function in patients is normal. However, lemon candy increases not only salivary flow but also salivary gland blood flow (Fig. 4). Doppler sonographic studies demonstrated a significant increase in blood flow in the major salivary glands after the use of sialogogue (19–22) in both normal and pathologic conditions. It is anticipated that ^{131}I uptake in iodine-avid tissues, including salivary glands, rises up to 24 h after ingestion of ^{131}I . Because ^{131}I uptake by the remnant thyroid or metastatic thyroid cancer is substantially lower than the normal thyroid gland and clearance of ^{131}I from the systemic circulation may be delayed due to a decreased glomerular filtration rate in the hypothyroid condition, the blood concentration of ^{131}I at an early period after ^{131}I ingestion should be considerably high. If continuous sucking of lemon candy constantly enhances blood flow to the salivary gland, a greater amount of ^{131}I may be delivered to the salivary glands. After 24 h after ingestion, ^{131}I uptake

TABLE 2

Comparison of Incidence of Salivary Side Effects After High-Dose Radioiodine Therapy Between Group A and Group B

Event	Incidence* (%)		P
	Group A (n = 105)	Group B (n = 125)	
Sialoadenitis	63.8 (67/105)	36.8 (46/125)	<0.001
Taste dysfunction	39.0 (41/105)	25.6 (32/125)	<0.01
Dry mouth	23.8 (25/105)	11.2 (14/125)	<0.005
Xerostomia	14.3 (15/105)	5.6 (7/125)	<0.05

*Values in parentheses are numbers of patients.

TABLE 3
Salivary Gland Involvement

Group	No. of patients						PTG and SMG*
	PTG			SMG			
	Unilateral	Bilateral	Total	Unilateral	Bilateral	Total	
A	7	30	37	6	19	25	5
B	3	22	25	5	14	19	2

*Involvement of all 4 major glands.

PTG = parotid gland; SMG = submandibular gland.

by iodine-avid tissues reaches a plateau and the majority of radioactivity is excreted into the urine. Subsequent sucking of lemon candy does not further increase ^{131}I uptake in the salivary glands and predominantly helps wash ^{131}I out from the salivary glands. Additionally, it is uncertain whether salivary gland function is really preserved in every thyroidectomized patient in a hypothyroid condition. Animal studies suggest that hypothyroidism modifies saliva secretion as well as the morphologic structure of the salivary gland (1,23–25). Caglar et al. pointed out that patients who underwent a large resection tended to show a higher incidence of salivary gland dysfunction after ^{131}I therapy (17). Additionally, enlarged salivary glands are not an uncommon finding in patients with hypothyroidism (26). Sialogogue may inadequately stimulate saliva secretion in a subset of patients with an impaired patency of the salivary duct to enhance stasis of ^{131}I in the duct. The effects of neck dissection and thyroid hormone withdrawal on salivary gland function need to be investigated further. With the use of recombinant human thyroid-stimulating hormone (rhTSH), radioiodine kinetics and salivary or renal functions in the patients are expected to be normal (27–30). It will be interesting to investigate the incidence of salivary side effects in patients undergoing radioimmunotherapy (RIT) with rhTSH treatment.




FIGURE 4. Power mode Doppler ultrasonography in healthy subject at rest (right) and at simulated condition by lemon candy (left). By use of lemon candy, contraction of gland was associated with increase in blood flow (orange color).

The major limitation of our study is that it was neither double blinded nor controlled. We did not have a group without lemon candy sucking. On encountering unexpectedly higher salivary side effects in group A, the patients in group B tended to be treated more intensively with steroids or nonsteroidal antiinflammatory drugs for sialoadenitis and with a drug containing zinc acetate or vitamin B₁₂ for taste dysfunction. The follow-up period after RIT was not identical in the 2 groups. However, all side effects, including xerostomia, were apparent until 17 mo after RIT and the difference in the follow-up period must not have affected the frequency of salivary side effects observed. Another limitation was the diagnostic strategy for salivary gland dysfunction. In the process of this study, we encountered patients showing disagreements between subjective symptoms and salivary gland scintigraphy results with regard to a dry mouth. Some patients complained of dry mouth despite normal or mildly impaired salivary scintigraphy results. Other patients with impaired salivary gland scintigraphy results did not complain of a dry mouth. Such patients did not have a diagnosis of xerostomia. Although salivary gland scintigraphy is a useful tool in assessment of salivary function (31), overlapping in the quantitative parameter of salivary gland scintigraphy between xerostomic patients with Sjögren's syndrome and healthy control subjects has been reported (32). Similar to previous reports, we did not perform any tests to investigate the absolute salivary flow or take the effects of the drugs for an attempt of treating nonthyroidal complications, such as vasodepressors or tranquilizers, into consideration.

Meanwhile, it seems reasonable that lemon candy is administered in combination with drugs such as reserpine (33), atropine, or, ideally, amifostine since ^{131}I uptake in the salivary glands can be suppressed by these drugs. Moreover, it should be kept in mind that early use of sialogogue may enhance the salivary gland side effects of ^{131}I therapy. For preventing life-long salivary gland complications of ^{131}I therapy, the timing of lemon candy sucking should be carefully selected.

CONCLUSION

Stimulation of saliva flow by means of lemon candy in close temporal proximity to ^{131}I administration is associated with increased side effects on subsequent salivary gland function. Lemon candy should be given after 24 h following ^{131}I therapy.

REFERENCES

1. Viejo ADL, Dothan O, Levy O, Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. *Physiol Rev.* 2000;80:1083–1105.
2. Shen DH, Kloos RT, Mazzaferri EL, Jhiang SM. Sodium iodide symporter in health and disease. *Thyroid.* 2001;11:415–425.
3. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. *Thyroid.* 2003;13:265–271.
4. Allweiss P, Braunstein GD, Katz A, et al. Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication. *J Nucl Med.* 1984;25:755–758.
5. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. *Br J Radiol.* 1986;59:45–51.
6. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. *J Nucl Med.* 1998;39:1551–1554.
7. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. *J Nucl Med.* 2001;42:738–743.
8. Hoeizer A, Stiner D, Bauer D, et al. Current practice of radioiodine treatment in the management of different thyroid cancer in Germany. *Eur J Nucl Med.* 2000;27:1165–1172.
9. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid in cancer patients treated with radioiodine. *Int J Radiat Oncol Biol Phys.* 1996;35:535–540.
10. Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. *Clin Nucl Med.* 1996;21:780–782.
11. Bohuslavizki KH, Brenner W, Klutmann S, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. *J Nucl Med.* 1998;39:1237–1242.
12. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. *J Clin Oncol.* 1998;16:3542–3549.
13. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Radioprotection of salivary glands by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) obtained in a rabbit animal model. *Int J Radiat Oncol Biol Phys.* 1999;45:181–186.
14. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial. *Cancer Biother Radiopharm.* 1999;14:337–347.
15. McDougall RI. *Thyroid Disease in Clinical Practice.* London, U.K.: Chapman & Hall; 1992:215–230.
16. Wartofsky L. *Thyroid Cancer: A Comprehensive Guide To Clinical Management.* Totowa, NJ: Humana Press; 2000:155–162.
17. Caglar M, Tuncel M, Alpar R. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. *Clin Nucl Med.* 2002;27:767–771.
18. Bohuslavizki KH, Brenner W, Lassmann S, et al. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. *Nucl Med Commun.* 1996;17:681–686.
19. Arita T, Fujita T, Yoneshiro S, et al. Usefulness of color Doppler flow imaging for blood flow in salivary gland. *Nippon Igaku Hoshasen Gakkai Zasshi.* 1993;53:865–877.
20. Carotti M, Salaffi F, Manganelli P, Argalia G. Ultrasonography and colour Doppler sonography of salivary glands in primary Sjogren's syndrome. *Clin Rheumatol.* 2001;20:213–219.
21. Martinoli C, Derchi LE, Solbiati L, Rizzatto G, Silvestri E, Giannoni M. Color Doppler sonography of salivary glands. *AJR.* 1994;163:933–941.
22. Ariji R, Yuasa H, Ariji E. High-frequency color Doppler sonography of the submandibular gland. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1998;86:476–481.
23. Noorafshan A. Stereological study on the submandibular gland in hypothyroid rats. *APMIS.* 2001;109:223–227.
24. Tumilasci OR, Houssay AB, Paz CV, Sosto NE, Varela V. Influence of thyroid function upon "substance P" induced secretion of saliva by submaxillary glands. *Horm Metab Res.* 1986;18:234–237.
25. Tumilasci OR, Houssay AB, Sosto NE, Paz CV, Varela V. Thyroid hormone modulation of VIP's induced salivary secretion in the submaxillary glands of rats. *J Endocrinol Invest.* 1986;9:51–55.
26. Fulop M. Pouting sublinguals: enlarged salivary glands in myxoedema. *Lancet.* 1989;2:550–551.
27. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. *Eur J Nucl Med Mol Imaging.* 2003;30:1371–1377.
28. Sisson JC, Shulkin BL, Lawson S. Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of ^{131}I . *J Nucl Med.* 2003;44:898–903.
29. de Keizer B, Brans B, Hoekstra A, et al. Tumor dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. *Eur J Nucl Med Mol Imaging.* 2003;30:367–373.
30. Menzel C, Kranert WT, Dobernt N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of ^{131}I . *J Nucl Med.* 2003;44:1065–1068.
31. Loutfi I, Nair MK, Ebrahim AK. Salivary gland scintigraphy: the use of semi-quantitative analysis for uptake and clearance. *J Nucl Med Technol.* 2003;31:81–85.
32. Adams BK, Al Attia HM, Parkar S. Salivary gland scintigraphy in Sjogren's syndrome: are quantitative indices the answer? *Nucl Med Commun.* 2003;24:1011–1016.
33. Levy HA, Park CH. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. *Clin Nucl Med.* 1987;12:303–307.